Market closed

Astria Therapeutics/$ATXS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Ticker

$ATXS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

Website

www.astriatx.com

ATXS Metrics

BasicAdvanced

$421M

-

-$1.97

0.71 -

Price and volume

Market cap

$421M

Beta

0.71

52-week high

$16.90

52-week low

$6.94

Average daily volume

347K

Financial strength

Current ratio

22.377

Quick ratio

21.895

Long term debt to equity

1.247

Total debt to equity

1.65

Management effectiveness

Return on assets (TTM)

-22.72%

Return on equity (TTM)

-38.03%

Valuation

Price to book

1.71

Price to tangible book (TTM)

1.71

Price to free cash flow (TTM)

-4.012

Growth

Earnings per share change (TTM)

-7.59%

3-year earnings per share growth (CAGR)

-61.18%

What the Analysts think about ATXS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.

ATXS Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ATXS Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ATXS News

AllArticlesVideos

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 weeks ago

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 month ago

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ATXS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Astria Therapeutics stock?

Astria Therapeutics (ATXS) has a market cap of $421M as of January 15, 2025.

What is the P/E ratio for Astria Therapeutics stock?

The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of January 15, 2025.

Does Astria Therapeutics stock pay dividends?

No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Astria Therapeutics dividend payment date?

Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Astria Therapeutics?

Astria Therapeutics (ATXS) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.